Key Points
- CEO Nello Mainolfi sold 30,000 Kymera shares at an average price of $113.80, generating $3.41 million and reducing his direct stake by 4.31% to 666,568 shares.
- Kymera reported stronger-than-expected quarterly results, with an adjusted loss of $0.62 per share versus the $0.71 consensus estimate and revenue of $65 million, up 465.2% year over year.
- Investor sentiment remains broadly positive: analysts give the stock a “Moderate Buy” consensus rating with an average price target of $133.21, while several institutional investors recently increased or initiated positions.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares of the company's stock, valued at $75,855,438.40. The trade was a 4.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Nello Mainolfi also recently made the following trade(s):
- On Tuesday, July 7th, Nello Mainolfi sold 50,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00.
Kymera Therapeutics Trading Down 1.5%
NASDAQ:KYMR opened at $110.12 on Friday. The firm's fifty day simple moving average is $114.69 and its 200 day simple moving average is $98.87. Kymera Therapeutics, Inc. has a twelve month low of $54.35 and a twelve month high of $130.05. The firm has a market capitalization of $9.16 billion, a price-to-earnings ratio of -33.99 and a beta of 1.98.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same period in the prior year, the firm earned ($0.95) EPS. The firm's quarterly revenue was up 465.2% compared to the same quarter last year. On average, analysts predict that Kymera Therapeutics, Inc. will post -3.83 earnings per share for the current year.
Institutional Investors Weigh In On Kymera Therapeutics
A number of institutional investors have recently made changes to their positions in KYMR. BlackRock Inc. bought a new stake in shares of Kymera Therapeutics in the 2nd quarter worth approximately $635,067,000. Baker BROS. Advisors LP grew its stake in Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock worth $581,610,000 after buying an additional 1,124,747 shares during the period. Merck & Co. Inc. bought a new stake in Kymera Therapeutics in the second quarter valued at $88,544,161. Finally, Bank of America Corp DE acquired a new position in shares of Kymera Therapeutics during the second quarter valued at $43,378,000.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on KYMR shares. Wells Fargo & Company boosted their price target on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an "overweight" rating in a research report on Thursday, August 27th. Piper Sandler reiterated an "overweight" rating and set a $140.00 price objective on shares of Kymera Therapeutics in a research note on Wednesday, September 23rd. Stifel Nicolaus boosted their target price on shares of Kymera Therapeutics from $132.00 to $152.00 and gave the stock a "buy" rating in a research report on Tuesday, September 22nd. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a research note on Monday, June 8th. Finally, B. Riley Financial lifted their price target on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a "buy" rating in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $133.21.
Get Our Latest Analysis on Kymera Therapeutics
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs.
Kymera's research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
